Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage ...

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...

Data was presented from a 26-week add-on study on Tresiba. Patients were divided into three arms: patients with HbA1c below 7% received once-daily Tresiba and metformin; patients with HbA1c above 7% ...

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tresiba® (insulin degludec) for the treatment of diabetes. Tresiba® is a new generation of once-daily ...

Novo Nordisk's long-acting insulin Tresiba is set to gain new hypoglycaemia prevention claims in Europe, giving it an advantage over Sanofi’s top-selling Lantus. Europe's CHMP committee has just ...

Tresiba (insulin degludec) may not be safe to use while pregnant or breastfeeding. Factors including the form you take or the condition being treated may determine whether you should use the drug ...

Novo Nordisk ( NVO) recently presented new data on its type II diabetes drug, Tresiba (degludec), from a one-year extension study, BEGIN ONCE LONG. Data from the study was presented at the 73 rd ...

The primary endpoint was defined as the first occurrence of CV death, non-fatal myocardial infarction or non-fatal stroke Novo Nordisk announced top data from the DEVOTE trial confirming the ...

Denmark based Novo Nordisk (NVO) recently announced that its candidate Tresiba (insulin degludec) has received approval in Japan. The Japanese Ministry of Health, Labour and Welfare (:MHLW) approved ...

Novo Nordisk's long-acting insulin Tresiba has been approved for routine use by NHS Wales as an option for treating diabetes. Novo Nordisk’s long-acting insulin Tresiba has been approved for use by ...

COPENHAGEN (Reuters) – Denmark’s Novo Nordisk, the world’s biggest insulin producer, said on Monday it got the final go-ahead from authorities to market its long-acting diabetes drug Tresiba in Europe ...